Immunotherapy and radiation for early-stage hodgkin lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This trial combines an immunotherapy drug (a type of treatment that helps your immune system fight cancer) with radiation therapy for people with early-stage classic Hodgkin lymphoma. The goal is to see if this combination can treat the cancer effectively while possibly reducing side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- A first diagnosis of classic Hodgkin lymphoma (a cancer of the lymph system)
- Stage I or II (meaning the disease is early stage and confined to one or two areas of the body)
- No 'risk factors' such as a large chest tumor, tumor in other organs, a high ESR blood test, or involvement of 3 or more lymph node areas
- No prior treatment for Hodgkin lymphoma (no chemotherapy, radiation, or stem cell transplant)
- Not pregnant or breastfeeding
- Able to follow the study plan (follow medical instructions)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether combining the immunotherapy drug pembrolizumab (Keytruda) with the chemotherapy bendamustine can help people with Hodgkin lymphoma whose cancer returned or did not respond to earlier treatment. The goal is to see if this two-drug combination works better than either drug alone.
This Phase 2 study tests whether pembrolizumab combined with salvage (second-line) chemotherapy can treat people whose classical Hodgkin lymphoma has either come back after initial treatment or did not respond to initial treatment. You may benefit if you have first-relapsed or refractory classical Hodgkin lymphoma and meet other study rules.
This trial studies a customized immune-based treatment approach for people with early-stage “unfavorable” classical Hodgkin lymphoma who have not had prior treatment. It may help by targeting your lymphoma using an individualized plan based on your case.
This trial tests a drug called pembrolizumab as the first treatment for advanced-stage classical Hodgkin lymphoma. It may help shrink tumors and keep the disease from getting worse.
This study tests a combination of the immunotherapy drug pembrolizumab with a chemotherapy regimen called GVD for patients whose Hodgkin's lymphoma has not responded or has returned after initial treatment. The goal is to see if this combination works better than standard approaches.
This trial tests a new combination of two immunotherapy drugs (IMM01 and tislelizumab) compared with standard chemotherapy for people with classical Hodgkin lymphoma that has not responded to PD-1/PD-L1 inhibitors. The goal is to see if this new approach can help when other treatments have failed.
Hear when a new Classical Hodgkin Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.